It is a drug that suppresses muscle spasms, a type of antispasmodic used for smooth muscle contraction, especially in the tubular organs of the gastrointestinal tract.
Market Analysis and Insights: Global Antispasmodics Drug Market
Prior to COVID-19, the market for Antispasmodics Drug was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 2021–2026, whereas post-COVID-19 scenario, the market for Antispasmodics Drug is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Antispasmodics Drug market.
Global Antispasmodics Drug Scope and Market Size
Antispasmodics Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Antispasmodics Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Antispasmodics Drug market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Antispasmodics Drug industry.
The following players are covered in this report:
Allergan
Hikma Pharmaceutical
Lannett
Mylan
Nexus Pharmaceuticals
Akorn
Aurobindo Pharma
Daiichi Sankyo
Fresenius Kabi
Shanghai Fosun Pharmaceutical（Group）
SunGen Pharma
Antispasmodics Drug Breakdown Data by Type
Dicyclomine Hydrochloride
Loperamide Hydrochloride
Others
Antispasmodics Drug Breakdown Data by Application
Hospital
Homecare
Specialty Clinic
Others
Market Analysis and Insights: Global Antispasmodics Drug Market
Prior to COVID-19, the market for Antispasmodics Drug was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 2021–2026, whereas post-COVID-19 scenario, the market for Antispasmodics Drug is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Antispasmodics Drug market.
Global Antispasmodics Drug Scope and Market Size
Antispasmodics Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Antispasmodics Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Antispasmodics Drug market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Antispasmodics Drug industry.
The following players are covered in this report:
Allergan
Hikma Pharmaceutical
Lannett
Mylan
Nexus Pharmaceuticals
Akorn
Aurobindo Pharma
Daiichi Sankyo
Fresenius Kabi
Shanghai Fosun Pharmaceutical（Group）
SunGen Pharma
Antispasmodics Drug Breakdown Data by Type
Dicyclomine Hydrochloride
Loperamide Hydrochloride
Others
Antispasmodics Drug Breakdown Data by Application
Hospital
Homecare
Specialty Clinic
Others
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Antispasmodics Drug Revenue
1.4 Covid-19 Implications on Market by Type
1.4.1 Global Antispasmodics Drug Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Dicyclomine Hydrochloride
1.4.3 Loperamide Hydrochloride
1.4.4 Others
1.5 Market by Application
1.5.1 Global Antispasmodics Drug Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Homecare
1.5.4 Specialty Clinic
1.5.5 Others
1.6 Coronavirus Disease 2019 (Covid-19): Antispasmodics Drug Industry Impact
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Covid-19 Implications on Global Antispasmodics Drug Market Perspective (2015-2026)
2.2 Covid-19 Implications on Global Antispasmodics Drug Growth Trends by Regions
2.2.1 Antispasmodics Drug Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Antispasmodics Drug Historic Market Share by Regions (2015-2020)
2.2.3 Antispasmodics Drug Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Antispasmodics Drug Market Growth Strategy
2.3.6 Primary Interviews with Key Antispasmodics Drug Players (Opinion Leaders)
3 Covid-19 Implications on Competition Landscape by Key Players
3.1 Global Top Antispasmodics Drug Players by Market Size
3.1.1 Global Top Antispasmodics Drug Players by Revenue (2015-2020)
3.1.2 Global Antispasmodics Drug Revenue Market Share by Players (2015-2020)
3.1.3 Global Antispasmodics Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Antispasmodics Drug Market Concentration Ratio
3.2.1 Global Antispasmodics Drug Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Antispasmodics Drug Revenue in 2019
3.3 Antispasmodics Drug Key Players Head office and Area Served
3.4 Key Players Antispasmodics Drug Product Solution and Service
3.5 Date of Enter into Antispasmodics Drug Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Covid-19 Implications on Market Size by Type (2015-2026)
4.1 Global Antispasmodics Drug Historic Market Size by Type (2015-2020)
4.2 Global Antispasmodics Drug Forecasted Market Size by Type (2021-2026)
5 Covid-19 Implications on Market Size by Application (2015-2026)
5.1 Global Antispasmodics Drug Market Size by Application (2015-2020)
5.2 Global Antispasmodics Drug Forecasted Market Size by Application (2021-2026)
6 North America Impact of COVID-19
6.1 North America Antispasmodics Drug Market Size (2015-2020)
6.2 Antispasmodics Drug Key Players in North America (2019-2020)
6.3 North America Antispasmodics Drug Market Size by Type (2015-2020)
6.4 North America Antispasmodics Drug Market Size by Application (2015-2020)
7 Europe Impact of COVID-19
7.1 Europe Antispasmodics Drug Market Size (2015-2020)
7.2 Antispasmodics Drug Key Players in Europe (2019-2020)
7.3 Europe Antispasmodics Drug Market Size by Type (2015-2020)
7.4 Europe Antispasmodics Drug Market Size by Application (2015-2020)
8 China Impact of COVID-19
8.1 China Antispasmodics Drug Market Size (2015-2020)
8.2 Antispasmodics Drug Key Players in China (2019-2020)
8.3 China Antispasmodics Drug Market Size by Type (2015-2020)
8.4 China Antispasmodics Drug Market Size by Application (2015-2020)
9 Japan Impact of COVID-19
9.1 Japan Antispasmodics Drug Market Size (2015-2020)
9.2 Antispasmodics Drug Key Players in Japan (2019-2020)
9.3 Japan Antispasmodics Drug Market Size by Type (2015-2020)
9.4 Japan Antispasmodics Drug Market Size by Application (2015-2020)
10 Southeast Asia Impact of COVID-19
10.1 Southeast Asia Antispasmodics Drug Market Size (2015-2020)
10.2 Antispasmodics Drug Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Antispasmodics Drug Market Size by Type (2015-2020)
10.4 Southeast Asia Antispasmodics Drug Market Size by Application (2015-2020)
11 India Impact of COVID-19
11.1 India Antispasmodics Drug Market Size (2015-2020)
11.2 Antispasmodics Drug Key Players in India (2019-2020)
11.3 India Antispasmodics Drug Market Size by Type (2015-2020)
11.4 India Antispasmodics Drug Market Size by Application (2015-2020)
12 Central & South America Impact of COVID-19
12.1 Central & South America Antispasmodics Drug Market Size (2015-2020)
12.2 Antispasmodics Drug Key Players in Central & South America (2019-2020)
12.3 Central & South America Antispasmodics Drug Market Size by Type (2015-2020)
12.4 Central & South America Antispasmodics Drug Market Size by Application (2015-2020)
13Key Players Profiles
13.1 Allergan
13.1.1 Allergan Company Details
13.1.2 Allergan Business Overview and Its Total Revenue
13.1.3 Allergan Antispasmodics Drug Introduction
13.1.4 Allergan Revenue in Antispasmodics Drug Business (2015-2020))
13.1.5 Allergan Recent Development and Reaction to COVID-19
13.2 Hikma Pharmaceutical
13.2.1 Hikma Pharmaceutical Company Details
13.2.2 Hikma Pharmaceutical Business Overview and Its Total Revenue
13.2.3 Hikma Pharmaceutical Antispasmodics Drug Introduction
13.2.4 Hikma Pharmaceutical Revenue in Antispasmodics Drug Business (2015-2020)
13.2.5 Hikma Pharmaceutical Recent Development and Reaction to COVID-19
13.3 Lannett
13.3.1 Lannett Company Details
13.3.2 Lannett Business Overview and Its Total Revenue
13.3.3 Lannett Antispasmodics Drug Introduction
13.3.4 Lannett Revenue in Antispasmodics Drug Business (2015-2020)
13.3.5 Lannett Recent Development and Reaction to COVID-19
13.4 Mylan
13.4.1 Mylan Company Details
13.4.2 Mylan Business Overview and Its Total Revenue
13.4.3 Mylan Antispasmodics Drug Introduction
13.4.4 Mylan Revenue in Antispasmodics Drug Business (2015-2020)
13.4.5 Mylan Recent Development and Reaction to COVID-19
13.5 Nexus Pharmaceuticals
13.5.1 Nexus Pharmaceuticals Company Details
13.5.2 Nexus Pharmaceuticals Business Overview and Its Total Revenue
13.5.3 Nexus Pharmaceuticals Antispasmodics Drug Introduction
13.5.4 Nexus Pharmaceuticals Revenue in Antispasmodics Drug Business (2015-2020)
13.5.5 Nexus Pharmaceuticals Recent Development and Reaction to COVID-19
13.6 Akorn
13.6.1 Akorn Company Details
13.6.2 Akorn Business Overview and Its Total Revenue
13.6.3 Akorn Antispasmodics Drug Introduction
13.6.4 Akorn Revenue in Antispasmodics Drug Business (2015-2020)
13.6.5 Akorn Recent Development and Reaction to COVID-19
13.7 Aurobindo Pharma
13.7.1 Aurobindo Pharma Company Details
13.7.2 Aurobindo Pharma Business Overview and Its Total Revenue
13.7.3 Aurobindo Pharma Antispasmodics Drug Introduction
13.7.4 Aurobindo Pharma Revenue in Antispasmodics Drug Business (2015-2020)
13.7.5 Aurobindo Pharma Recent Development and Reaction to COVID-19
13.8 Daiichi Sankyo
13.8.1 Daiichi Sankyo Company Details
13.8.2 Daiichi Sankyo Business Overview and Its Total Revenue
13.8.3 Daiichi Sankyo Antispasmodics Drug Introduction
13.8.4 Daiichi Sankyo Revenue in Antispasmodics Drug Business (2015-2020)
13.8.5 Daiichi Sankyo Recent Development and Reaction to COVID-19
13.9 Fresenius Kabi
13.9.1 Fresenius Kabi Company Details
13.9.2 Fresenius Kabi Business Overview and Its Total Revenue
13.9.3 Fresenius Kabi Antispasmodics Drug Introduction
13.9.4 Fresenius Kabi Revenue in Antispasmodics Drug Business (2015-2020)
13.9.5 Fresenius Kabi Recent Development and Reaction to COVID-19
13.10 Shanghai Fosun Pharmaceutical（Group）
13.10.1 Shanghai Fosun Pharmaceutical（Group） Company Details
13.10.2 Shanghai Fosun Pharmaceutical（Group） Business Overview and Its Total Revenue
13.10.3 Shanghai Fosun Pharmaceutical（Group） Antispasmodics Drug Introduction
13.10.4 Shanghai Fosun Pharmaceutical（Group） Revenue in Antispasmodics Drug Business (2015-2020)
13.10.5 Shanghai Fosun Pharmaceutical（Group） Recent Development and Reaction to COVID-19
13.11 SunGen Pharma
10.11.1 SunGen Pharma Company Details
10.11.2 SunGen Pharma Business Overview and Its Total Revenue
10.11.3 SunGen Pharma Antispasmodics Drug Introduction
10.11.4 SunGen Pharma Revenue in Antispasmodics Drug Business (2015-2020)
10.11.5 SunGen Pharma Recent Development and Reaction to COVID-19
14Analyst's Viewpoints/Conclusions
15Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Antispasmodics Drug Revenue
1.4 Covid-19 Implications on Market by Type
1.4.1 Global Antispasmodics Drug Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Dicyclomine Hydrochloride
1.4.3 Loperamide Hydrochloride
1.4.4 Others
1.5 Market by Application
1.5.1 Global Antispasmodics Drug Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Homecare
1.5.4 Specialty Clinic
1.5.5 Others
1.6 Coronavirus Disease 2019 (Covid-19): Antispasmodics Drug Industry Impact
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Covid-19 Implications on Global Antispasmodics Drug Market Perspective (2015-2026)
2.2 Covid-19 Implications on Global Antispasmodics Drug Growth Trends by Regions
2.2.1 Antispasmodics Drug Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Antispasmodics Drug Historic Market Share by Regions (2015-2020)
2.2.3 Antispasmodics Drug Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Antispasmodics Drug Market Growth Strategy
2.3.6 Primary Interviews with Key Antispasmodics Drug Players (Opinion Leaders)
3 Covid-19 Implications on Competition Landscape by Key Players
3.1 Global Top Antispasmodics Drug Players by Market Size
3.1.1 Global Top Antispasmodics Drug Players by Revenue (2015-2020)
3.1.2 Global Antispasmodics Drug Revenue Market Share by Players (2015-2020)
3.1.3 Global Antispasmodics Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Antispasmodics Drug Market Concentration Ratio
3.2.1 Global Antispasmodics Drug Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Antispasmodics Drug Revenue in 2019
3.3 Antispasmodics Drug Key Players Head office and Area Served
3.4 Key Players Antispasmodics Drug Product Solution and Service
3.5 Date of Enter into Antispasmodics Drug Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Covid-19 Implications on Market Size by Type (2015-2026)
4.1 Global Antispasmodics Drug Historic Market Size by Type (2015-2020)
4.2 Global Antispasmodics Drug Forecasted Market Size by Type (2021-2026)
5 Covid-19 Implications on Market Size by Application (2015-2026)
5.1 Global Antispasmodics Drug Market Size by Application (2015-2020)
5.2 Global Antispasmodics Drug Forecasted Market Size by Application (2021-2026)
6 North America Impact of COVID-19
6.1 North America Antispasmodics Drug Market Size (2015-2020)
6.2 Antispasmodics Drug Key Players in North America (2019-2020)
6.3 North America Antispasmodics Drug Market Size by Type (2015-2020)
6.4 North America Antispasmodics Drug Market Size by Application (2015-2020)
7 Europe Impact of COVID-19
7.1 Europe Antispasmodics Drug Market Size (2015-2020)
7.2 Antispasmodics Drug Key Players in Europe (2019-2020)
7.3 Europe Antispasmodics Drug Market Size by Type (2015-2020)
7.4 Europe Antispasmodics Drug Market Size by Application (2015-2020)
8 China Impact of COVID-19
8.1 China Antispasmodics Drug Market Size (2015-2020)
8.2 Antispasmodics Drug Key Players in China (2019-2020)
8.3 China Antispasmodics Drug Market Size by Type (2015-2020)
8.4 China Antispasmodics Drug Market Size by Application (2015-2020)
9 Japan Impact of COVID-19
9.1 Japan Antispasmodics Drug Market Size (2015-2020)
9.2 Antispasmodics Drug Key Players in Japan (2019-2020)
9.3 Japan Antispasmodics Drug Market Size by Type (2015-2020)
9.4 Japan Antispasmodics Drug Market Size by Application (2015-2020)
10 Southeast Asia Impact of COVID-19
10.1 Southeast Asia Antispasmodics Drug Market Size (2015-2020)
10.2 Antispasmodics Drug Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Antispasmodics Drug Market Size by Type (2015-2020)
10.4 Southeast Asia Antispasmodics Drug Market Size by Application (2015-2020)
11 India Impact of COVID-19
11.1 India Antispasmodics Drug Market Size (2015-2020)
11.2 Antispasmodics Drug Key Players in India (2019-2020)
11.3 India Antispasmodics Drug Market Size by Type (2015-2020)
11.4 India Antispasmodics Drug Market Size by Application (2015-2020)
12 Central & South America Impact of COVID-19
12.1 Central & South America Antispasmodics Drug Market Size (2015-2020)
12.2 Antispasmodics Drug Key Players in Central & South America (2019-2020)
12.3 Central & South America Antispasmodics Drug Market Size by Type (2015-2020)
12.4 Central & South America Antispasmodics Drug Market Size by Application (2015-2020)
13Key Players Profiles
13.1 Allergan
13.1.1 Allergan Company Details
13.1.2 Allergan Business Overview and Its Total Revenue
13.1.3 Allergan Antispasmodics Drug Introduction
13.1.4 Allergan Revenue in Antispasmodics Drug Business (2015-2020))
13.1.5 Allergan Recent Development and Reaction to COVID-19
13.2 Hikma Pharmaceutical
13.2.1 Hikma Pharmaceutical Company Details
13.2.2 Hikma Pharmaceutical Business Overview and Its Total Revenue
13.2.3 Hikma Pharmaceutical Antispasmodics Drug Introduction
13.2.4 Hikma Pharmaceutical Revenue in Antispasmodics Drug Business (2015-2020)
13.2.5 Hikma Pharmaceutical Recent Development and Reaction to COVID-19
13.3 Lannett
13.3.1 Lannett Company Details
13.3.2 Lannett Business Overview and Its Total Revenue
13.3.3 Lannett Antispasmodics Drug Introduction
13.3.4 Lannett Revenue in Antispasmodics Drug Business (2015-2020)
13.3.5 Lannett Recent Development and Reaction to COVID-19
13.4 Mylan
13.4.1 Mylan Company Details
13.4.2 Mylan Business Overview and Its Total Revenue
13.4.3 Mylan Antispasmodics Drug Introduction
13.4.4 Mylan Revenue in Antispasmodics Drug Business (2015-2020)
13.4.5 Mylan Recent Development and Reaction to COVID-19
13.5 Nexus Pharmaceuticals
13.5.1 Nexus Pharmaceuticals Company Details
13.5.2 Nexus Pharmaceuticals Business Overview and Its Total Revenue
13.5.3 Nexus Pharmaceuticals Antispasmodics Drug Introduction
13.5.4 Nexus Pharmaceuticals Revenue in Antispasmodics Drug Business (2015-2020)
13.5.5 Nexus Pharmaceuticals Recent Development and Reaction to COVID-19
13.6 Akorn
13.6.1 Akorn Company Details
13.6.2 Akorn Business Overview and Its Total Revenue
13.6.3 Akorn Antispasmodics Drug Introduction
13.6.4 Akorn Revenue in Antispasmodics Drug Business (2015-2020)
13.6.5 Akorn Recent Development and Reaction to COVID-19
13.7 Aurobindo Pharma
13.7.1 Aurobindo Pharma Company Details
13.7.2 Aurobindo Pharma Business Overview and Its Total Revenue
13.7.3 Aurobindo Pharma Antispasmodics Drug Introduction
13.7.4 Aurobindo Pharma Revenue in Antispasmodics Drug Business (2015-2020)
13.7.5 Aurobindo Pharma Recent Development and Reaction to COVID-19
13.8 Daiichi Sankyo
13.8.1 Daiichi Sankyo Company Details
13.8.2 Daiichi Sankyo Business Overview and Its Total Revenue
13.8.3 Daiichi Sankyo Antispasmodics Drug Introduction
13.8.4 Daiichi Sankyo Revenue in Antispasmodics Drug Business (2015-2020)
13.8.5 Daiichi Sankyo Recent Development and Reaction to COVID-19
13.9 Fresenius Kabi
13.9.1 Fresenius Kabi Company Details
13.9.2 Fresenius Kabi Business Overview and Its Total Revenue
13.9.3 Fresenius Kabi Antispasmodics Drug Introduction
13.9.4 Fresenius Kabi Revenue in Antispasmodics Drug Business (2015-2020)
13.9.5 Fresenius Kabi Recent Development and Reaction to COVID-19
13.10 Shanghai Fosun Pharmaceutical（Group）
13.10.1 Shanghai Fosun Pharmaceutical（Group） Company Details
13.10.2 Shanghai Fosun Pharmaceutical（Group） Business Overview and Its Total Revenue
13.10.3 Shanghai Fosun Pharmaceutical（Group） Antispasmodics Drug Introduction
13.10.4 Shanghai Fosun Pharmaceutical（Group） Revenue in Antispasmodics Drug Business (2015-2020)
13.10.5 Shanghai Fosun Pharmaceutical（Group） Recent Development and Reaction to COVID-19
13.11 SunGen Pharma
10.11.1 SunGen Pharma Company Details
10.11.2 SunGen Pharma Business Overview and Its Total Revenue
10.11.3 SunGen Pharma Antispasmodics Drug Introduction
10.11.4 SunGen Pharma Revenue in Antispasmodics Drug Business (2015-2020)
10.11.5 SunGen Pharma Recent Development and Reaction to COVID-19
14Analyst's Viewpoints/Conclusions
15Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
